The far most remarkable responses with CD19 redirected T cells have been reported by groups at UPENN, Memorial Sloan Kettering Cancer Center (MSKCC), and NCI in patients with resistant or relapsed acute lymphoblastic leukemia (ALL) with CR rates ranging from 70 to 90% in approximately 65 patients among the three trials, combined [37–39]. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.